Background The aim of this study was to determine morbidity and 30-day mortality rates of thoracic endovascular aortic repair (TEVAR) for Stanford B dissection over a 16-year period and determine if these rates have improved with better stent-graft technology and surgical technique. Methods Electronic databases were searched in all languages and a systematic review conducted. A comparison of the early (1998-2007 ¼ 787 patients) and later (2007-2013 ¼ 787 patients) halves of the patient population was done. Studies were chosen based on availability of details regarding morbidity and mortality. Ambiguous studies were excluded. Results A total of 69 suitable studies published between 1998 and 2013 (1,574 patients) were examined including 1 randomized control trial, 55 retrospective studies, 3 prospective, 1 mixed, and 9 case reports. Overall mortality and morbidity rates for TEVAR was 8.07% (n ¼ 127) and 30.8% (n ¼ 485), respectively. The stent-graft-related death rate was 6.20% (97 cases excluding medically related deaths). The endoleak rate was 5.9% of which most were type I. Major complications include stroke (2.7%), paraplegia (1.9%), partial thrombosis of false lumen (2.5%), retrograde type A dissection (3.1%), visceral malperfusion (2.0%), conversion to open intervention (1.9%), and secondary intervention (4.1%). The stent-graft-related mortality rate increased in the 2007 to 2013 group compared with the 1998 to 2007 group (56.2 vs. 24% of patients who died; p < 0.05). There was also an increase in the overall morbidity rates from 25% (1998-2007) to 36.6% (2007-2013) but did not reach statistical significance p > 0.05. Conclusion Mortality and morbidity rates for TEVAR seemed to have increased over the past 16 years despite improved technology and surgical technique. This may be explained by the increasing liberal use of TEVAR intervention and quite possibly better reporting. The current data are highly heterogenous making it difficult for solid conclusions to be drawn. The only way forward is through better data registries and well-designed clinical trials.
Introduction
The first endoluminal procedure was conducted by Dotter and 
Methodology
A systematic review was conducted using separate search strategies in the PubMed, MeSH thesaurus, and Cochrane databases. The following registries were included: EUROSTAR Registry, United Kingdom Thoracic Endograft Registry, and International Registry of Acute Aortic Dissection. The PRISMA guidelines were followed as recommended for systematic review reporting.
PICOS Statement
The study was conducted focusing on the 30-day mortality and morbidity of symptomatic type B acute and/or chronic aortic dissections (S-B-AD). Suitable studies for 16 years from 1998 to 2013 were selected for analysis. The objectives of the study were to determine overall rates for the 16-year period and to perform a comparison of the first (787 patients from 1998 to 2007) and later (787 patients from 2007 to 2013) halves of the patient population to determine if rates have improved with the advent of improved technology and surgical techniques.
Protocol and Registration
No review protocol was created online.
Eligibility Criteria
Suitable studies were chosen based on the accuracy of documentation of 30-day mortality and morbidity specifically for the S-B-AD. Once the information was clearly documented, the study was included.
Information Sources
A systematic review was conducted using separate search strategies in the following databases: PubMed, MeSH thesaurus, and Cochrane databases. The Embase, Ingenta, Zetoc, and Ovid databases were also used as well as the following registries were included: EUROSTAR Registry, United Kingdom Thoracic Endograft Registry, and International Registry of Acute Aortic Dissection.
Search
A standard PubMed search using the "Advanced Search Option" for matching terms was first used to obtain the meta-analyses, review articles, and case series on the treatment of S-B-AD, whether acute or chronic as well as involving consequent aneurysm formation or not. The search topics included the following:
1. "Type B dissection and descending thoracic dissection" 2. "Medical treatment" 3. "Open surgery" 4. "Endovascular/stent repair" Combinations were done using the "AND" option. This obtained the following results:
• "Type B dissection and descending thoracic dissection" yielded 340 articles. • The 340 articles were then combined using the "AND" option in the search box yielding 108 for medical treatment, 69 for open surgery, and 44 for endovascular/stent repair. There were 51 suitable articles selected for analysis.
Another search strategy was employed by searching through a MeSH search in PubMed combining "Aortic Aneurysm, Thoracic [MeSH] " AND "Stents [MeSH]" AND "Aneurysm, dissecting [MeSH] ." This yielded 441 articles from which the search was confined to clinical trials (three selected), review articles (two selected), randomized controlled trials (one selected), and meta-analyses (six selected).
The databases from the Cochrane library, Embase, Ingenta, Zetoc, and Ovid did not yield any new relevant information; however, hand-searching relevant references obtained via a standard PubMed search for the topic yielded a further 14 relevant articles.
Cumulatively, 69 suitable studies were selected. The six meta-analyses and two reviews were excluded to avoid duplicating data (►Fig. 1). A total of 1,574 patients were treated for S-B-AD. There were no ethical considerations. Results were entered into SPSS 20 (IBM SPSS 20 STATISTIC, United States) and analyzed using Pearson chi-square testing.
Results
A total of 69 articles with 1,574 patients were selected for the 16-year period, 1998 to 2013. Most included a mix of various types of descending thoracic aortic pathology including acute rupture, chronic aneurysmal disease, Stanford type A and B dissections, and traumatic disruption. Selected articles contained a detailed breakdown of the results, patient demographics, and details of complications associated with S-B-AD (►Table 1).
Thoracic endovascular aortic repairs (TEVARs) were done in the following countries: 11 (16%) studies from China, Japan, and Korea in the Far East; 16 (23%) from the United States; and 38 (55%) from European region including Germany, Austria, France, United Kingdom, Switzerland, Norway, Sweden, Italy, Belgium, and Denmark and Turkey. There were two from Brazil and one from New Zealand and Canada each (6%). These were related to a variety of causes including procedurerelated false aneurysm rupture, retrograde type A dissection, ruptured type I endoleak, persistent visceral and lower limb malperfusion, aorto-esophageal fistula, further type B dissection, conversion to open surgery, as well as ruptured access vessels. There were 24 (1.52%) medical-related death within 30 days. The total number of deaths directly related to stenting was 97 (6.20%) (excluding medical-related deaths) within 30 days of TEVAR (►Table 2).
Procedure-related morbidities included retrograde type A dissection (49) , visceral malperfusion (32), lower limb ischemia (5), aorto-esophageal fistula (4), stroke (41) , paraplegia/ paraparesis (30), type I endoleak (82), type II endoleak (11) , partial thrombosis of the false lumen (39) , conversion to open surgery failed procedure (30) , secondary interventions (65), renal failure (31), device migration/modular disconnection/ junctional endoleaks (7), emboli (4), overstenting of the celiac artery (1), postimplantation syndrome (3), and failure (2). The overall morbidity rate for the patient population was 30.8% (►Table 3).
With regard to the comparison of the 1998 to 2007 period (787 patients) with the 2007 to 2013 period (787 patients), the findings were quite significant. The stent-graft-related mortality rates (which includes the subset of patients who died; n ¼ 127) doubled This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. There was no major statistical difference with regard to age or stent-graft used.
Discussion Background
Acute aortic syndrome describes the acute presentation of patients with characteristic aortic pain caused by potentially life-threatening thoracic aortic pathology. These include aortic dissection, intramural hematoma, penetrating aortic ulcer, aneurysmal leakage or rupture, and traumatic transaction. Aortic dissection can lead to aneurysm formation and its associated complications. The etiology is multifactorial with causes related to connective tissue or inherited disorders, developmental disorders associated with pregnancy, syphilis, crack cocaine usage, and cardiac catheterization.
Traditional management consisted of hypotensive medical management with open surgical intervention reserved for complicated cases with intractable pain, uncontrolled hypertension, progression of dissection, rupture, dilatation, lower limb ischemia, or visceral hypoperfusion.
13 Stent-graft technology has caused a paradigm shift in the approach for symptomatic cases. This is not without major risk which includes stroke, transient ischemic attacks, paraplegia, paraparesis, distal embolization, migration, endoleak, progressive dilatation, and inadvertent covering of arch or visceral vessels.
14

Literature Review
De Bakey et al 13 Recently, the first randomized control trial was published by Nienaber et al 7 in December 2009 and most of the studies have been retrospective observational studies. Nienaber et al randomized 72 patients to elective stent-graft repair with medical management and 68 patients to medical therapy alone with surveillance with the primary end point being allcause death at 2 years in uncomplicated type B aortic dissection. TEVAR failed to improve the 2-year survival and adverse event rates despite favorable aortic remodeling.
7,8
The NICE (National Institute for Clinical Excellence) guideline was based on a systematic review of published evidence commissioned by the institute with a total of 29 studies (27 case series and 2 comparative observational studies). In one comparative study, the technical success was 100% (67 patients) and overall technical success rate was 93% across 18 studies (16 case series and 2 comparative studies). The conversion to open rate varied from 0% (26 cases) to 7% (1 of 14 cases) and the number who developed aneurysmal dilatation varied from 0% (18 cases) to 7% (2 of 29 cases). The largest study of 84 patients showed an aneurysmal dilatation rate of 5% (4 of 84). The number of patients who experienced a decrease in aneurysm size varied from 100% in one study to 17% in another. Of relevance to this present article, the 30-day mortality by NICE varied from 0% in several studies with a combined population of 94 patients to 14% (2 of 14 patients). The overall mortality ranged from 3 to 24% across 17 studies with a mean follow-up of 14 months. The most common complication was endoleak with a mean incidence of 13% over 12 months (752 patients). In five studies, there were no endoleaks reported in 83 patients. In terms of major complications, injuries to access artery occurred in nine case series and included iliac artery dissection in one, perforation of the iliac artery in one, and rupture of the femoral artery in two cases. There were six cases of stent-graft migration in 15 case series. Other complications included wound problems in 25%, stroke in 19%, renal failure requiring dialysis in 11%, and paraplegia in 7%.
14
The article of Eggebrecht et al showed procedural success in 98% and major complications in 11% including a stroke rate of 0.8% and paraplegia of 1.9%. Overall complications were higher in acute dissections compared with chronic. Overall survival rates were 90% at 6 months and 88% at 2 years. 
15
In 2010, Nienaber et al critiqued the INSTEAD trial and concluded that there was no difference in all-cause mortality at 2 years, with cumulative survival of 95% with optimal medical therapy versus 88% with TEVAR (p ¼ 0.15). Aortarelated mortality was also not different (p ¼ 0.44) within the first 2 years of follow-up, and risk for the combined endpoints of aorta-related death (rupture) and progression (including conversion or additional endovascular or open surgery) was similar (p ¼ 0.65). They concluded that the data in the INSTEAD trial show that in the setting of clinically stable, so-called uncomplicated type B aortic dissection, elective stent-graft placement on top of optimized medical management fails to improve survival and adverse events within an observation period of 2 years, despite favorable aortic remodeling. 16 It seems that overall mortality and morbidity rates have been increased for TEVAR intervention for S-B-AD. This was demonstrated in the study herein presented, whereby the overall mortality and morbidity rates for TEVAR were 8.07% (n ¼ 127) and 30.8% (n ¼ 485), respectively. Additionally, the stent-graft-related mortality rate (which includes the subset of patients who died; n With respect to type I endoleak rates, this study showed a marginal increase in the leak rate from 39 in the 1998 to 2007 group to 43 in the 2007 to 2013 group with overall type I endoleak rates averaging 5.2%. Type II endoleaks also showed few numbers with an overall leak rate of < 0.1%.
Fattori et al
Retrograde aortic dissection accounted for 3.1% (49) of the study population with only a marginal increase from 21 to 28 in the 1998 to 2007 period and 2007 to 2013 periods, respectively. This is in keeping with most of the other studies with rates in a similar range.
Visceral malperfusion was, however, on a significant increase as seen from 5 in the 1998 to 2007 period compared with 27 cases in the 2007 to 2013 period. This may be explained by a more aggressive clinical approach to patient selection for S-B-AD and quite possibly better reporting leading to bias from previous inadequate data collection in older studies. This has occurred in spite of overall improvement in stent-graft technology and techniques. In conclusion, the data available are still too heterogeneous to make solid conclusions and the only way forward is through better data registries and well-designed clinical trials.
